Heart failure & cardiomyopathiesCohort study
Clonal Haematopoiesis is Associated with Major Adverse Cardiovascular Events in Patients with Hypertrophic Cardiomyopathy
- Cohort study
- biobank
Authors' conclusion
These results indicate that CH in patients with HCM is associated with worse clinical outcomes.
Study context
- Population
- Patients with hypertrophic cardiomyopathy (HCM) with available biospecimens, Peter Munk Cardiac Centre Cardiovascular Biobank
- Participants
- 799 patients
- Exposure
- Clonal haematopoiesis (CH) vs no CH
- CHn = 183
- Outcome
- Major adverse cardiovascular events (MACE):
- Appropriate ICD shock
- Stroke
- Cardiac arrest
- Orthotopic heart transplant
- Death
Main finding
MACE in HCM with sarcomeric germline mutations
Adjusted hazard ratio
6.89
95% CI 1.78–26.6
P = 0.005
CH vs No CH
adjusted HR 6.89 (95% CI 1.78–26.6); P = 0.005
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | adjusted HR (95% CI) | P value | |
|---|---|---|---|
| MACE with DNMT3A, TET2 and ASXL1 mutations | 5.76 (1.51–21.94) | P = 0.010 | |
| 0.050.21520Adjusted hazard ratio (log scale) |
- Prevalence of CH in HCM with sarcomeric germline mutations
- 22.9% · 183 of 183
Symptoms, fibrosis, cytokines and troponin I
- CH: more symptomatic and higher fibrosis burden than no CH
- IL-1ra, IL-6, IL-17F, TGFα, CCL21, CCL1, CCL8, CCL17 and troponin I upregulated in gene-positive HCM with CH
Original publication
Clonal Haematopoiesis is Associated with Major Adverse Cardiovascular Events in Patients with Hypertrophic Cardiomyopathy. Eur J Heart Fail. Published 1 August 2024. doi:10.1002/ejhf.3408
Summarised from the published abstract; every number is checked against it